Anixa Biosciences to Present at the 2026 Cantor Fitzgerald Global Healthcare Conference Highlighting its Breast Cancer Vaccine and Ovarian Cancer CAR-T Therapy

Conferencelira-celPositive

AI Analysis

Summary

Anixa Biosciences will present at the 2026 Cantor Fitzgerald Global Healthcare Conference, highlighting positive Phase 1 data for its breast cancer vaccine with all primary endpoints met and 74% of participants achieving protocol-defined immune responses, while its ovarian cancer CAR-T therapy lira-cel advances to the highest dose level in its fifth cohort.

Clinical Trial Data

Phase

Phase 1

Primary Endpoint

Met

Importance:6/10

Sentiment:

0.70

breast cancer vaccineovarian cancerCAR-T therapyPhase 1 dataPhase 2 preparationsconference presentationimmune response

Related Companies

$ANIX

Read the original article

Published by PR Newswire Clinical Trials on August 24, 2026 12:55 PM

Read Original